- Home
- AG vs CORT Comparison
AG vs CORT Comparison
Compare AG & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | CORT |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 3.7B |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | AG | CORT |
|---|---|---|
| Price | $24.88 | $32.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $21.92 | ★ $105.20 |
| AVG Volume (30 Days) | ★ 19.1M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $13.75 | $29.97 |
| Revenue Next Year | $26.43 | $30.25 |
| P/E Ratio | $143.01 | ★ $41.10 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $5.19 | $28.66 |
| 52 Week High | $32.00 | $117.33 |
Technical Indicators
Market Signals| Indicator | AG | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 30.61 |
| Support Level | $20.21 | $28.66 |
| Resistance Level | $27.90 | $41.92 |
| Average True Range (ATR) | 1.63 | 1.65 |
| MACD | -0.64 | 0.17 |
| Stochastic Oscillator | 6.56 | 5.99 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.